My Treatment Approach: Advancing Treatment Strategies for HER2+ Metastatic Breast Cancer

EP. 1: Clinical Scenario 1: A HER2+ mBC Patient With Trastuzumab Deruxtecan With Brain Mets

December 24th 2024

Panelists discuss how trastuzumab deruxtecan (Enhertu) is used to treat HER2-positive metastatic breast cancer with brain metastases, emphasizing its effectiveness in achieving systemic tumor reduction and CNS lesion stabilization while exploring treatment challenges and emerging strategies in this patient population.

EP. 2: Clinical Approaches in Treating HER2+ Breast Cancer and Brain Metastases

January 2nd 2025

Panelists discuss how they approach the treatment of HER2-positive advanced breast cancer with brain metastases, outlining the criteria for therapy selection, the role of patient-specific factors in shaping treatment strategies, and situations where they might adjust their approach.

EP. 3: T-DXd and the DESTINY-Breast12 Trial for HER2+ Advanced BC With or Without Brain Mets

January 14th 2025

Panelists discuss the DESTINY-Breast12 trial, reviewing its study design, rationale, and key efficacy and safety findings in HER2-positive metastatic breast cancer patients with brain metastases, focusing on differences in outcomes between patients with active vs stable brain metastases, and the role of trastuzumab deruxtecan (T-DXd) in expanding treatment options for this patient population.

EP. 4: The Impact of Trastuzumab Deruxtecan on Clinical Practice for HER2+ Advanced BC and Brain Mets

January 21st 2025

Panelists discuss how the DESTINY-Breast12 trial has influenced their approach to using trastuzumab deruxtecan (T-DXd) for patients with HER2-positive advanced breast cancer with brain metastases, highlighting the patient subgroups most likely to benefit from T-DXd and its impact on treatment sequencing for those with active brain metastases.